RBC Life Sciences (RBCL) 10-Q 14 Aug 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Aug. 01, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'RBC LIFE SCIENCES, INC.	'
Entity Central Index Key	'0000830052	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Document Type	'10-Q	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Amendment Flag	'false	'
Entity Common Stock, Shares Outstanding	'	2,212,350

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Jun. 30, 2014	Dec. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$2,113,171	$3,745,684
Accounts receivable, net of allowance for doubtful accounts of $34,000 and $28,000, respectively	839,983	907,287
Inventories	5,553,038	5,141,509
Deferred income taxes	443,463	429,640
Prepaid expenses and other current assets	746,332	793,548
Total current assets	9,695,987	11,017,668
Property and equipment, net	4,622,332	4,169,078
Goodwill, net	2,261,624	2,263,458
Intangible assets, net	62,770	37,979
Other assets, net	101,436	45,327
Total assets	16,744,149	17,533,510
Current liabilities:	'	'
Accounts payable, trade	2,101,993	1,608,000
Accrued liabilities	1,693,168	1,156,818
Current maturities of long-term obligations	220,841	212,474
Deferred revenue	2,474,042	3,677,893
Total current liabilities	6,490,044	6,655,185
Long-term obligations, less current maturities	1,023,794	1,136,347
Deferred income taxes	604,142	727,660
Commitments and contingencies	'	'
Shareholders’ equity:	'	'
Common stock, $0.001 par value; 50,000,000 shares authorized; 2,212,350 shares issued and outstanding at June 30, 2014 and December 31, 2013.	2,212	2,212
Additional paid-in capital	13,713,630	13,711,522
Accumulated deficit	-5,198,813	-4,814,281
Accumulated other comprehensive income	109,140	114,865
Total shareholders' equity	8,626,169	9,014,318
Total liabilities and shareholders' equity	$16,744,149	$17,533,510

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Current assets:	'	'
Allowance for doubtful accounts	$34,000	$28,000
Shareholders’ equity:	'	'
Common stock par value (in dollars per share)	$0.00	$0.00
Common stock shares authorized (shares)	50,000,000	50,000,000
Common stock shares issued (shares)	2,212,350	2,212,350
Common stock shares outstanding (shares)	2,212,350	2,212,350

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Comprehensive Income (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Statement of Comprehensive Income [Abstract]	'	'	'	'
Net sales	$7,885,090	$6,694,319	$13,598,210	$12,385,500
Cost of sales	3,762,809	3,723,744	6,293,844	6,441,997
Gross profit	4,122,281	2,970,575	7,304,366	5,943,503
Operating expenses:	'	'	'	'
General and administrative	2,679,105	2,329,950	5,399,711	4,498,697
Distributor commissions	1,278,347	711,616	2,112,810	1,365,867
Depreciation and amortization	131,639	126,861	250,849	253,371
Total operating expenses	4,089,091	3,168,427	7,763,370	6,117,935
Operating income (loss)	33,190	-197,852	-459,004	-174,432
Interest expense	24,456	28,391	49,924	57,720
Earnings (loss) before income taxes	8,734	-226,243	-508,928	-232,152
Provision (benefit) for income taxes	15,378	-78,939	-124,396	-77,172
Net loss	-6,644	-147,304	-384,532	-154,980
Other comprehensive income (loss):	'	'	'	'
Foreign currency translation adjustment	8,627	5,985	-5,725	27,984
Comprehensive income (loss)	$1,983	($141,319)	($390,257)	($126,996)
Net loss per share:	'	'	'	'
Basic (usd per share)	$0	($0.07)	($0.17)	($0.07)
Diluted (usd per share)	$0	($0.07)	($0.17)	($0.07)
Weighted average common shares outstanding:	'	'	'	'
Basic (shares)	2,212,350	2,222,883	2,212,350	2,222,883
Diluted (shares)	2,212,350	2,222,883	2,212,350	2,222,883

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities:	'	'
Net loss	($384,532)	($154,980)
Adjustment for non-cash items:	'	'
Depreciation and amortization	290,300	294,343
Stock-based compensation	2,107	9,474
Deferred income taxes and other	-137,621	3,848
Change in operating assets and liabilities:	'	'
Accounts receivable	67,300	-83,361
Inventories	-411,417	802,804
Prepaid expenses and other current assets	-56,962	-758,147
Other assets	-56,092	-107,150
Accounts payable and accrued liabilities	1,027,201	-386,408
Deferred revenue	-1,203,766	-375,803
Net cash used in operating activities	-863,482	-755,380
Cash flows from investing activities:	'	'
Purchase of property and equipment	-636,170	-11,292
Net cash used in investing activities	-636,170	-11,292
Cash flows from financing activities:	'	'
Payments of long-term obligations	-104,186	-96,441
Net cash used in financing activities	-104,186	-96,441
Effect of exchange rate changes on cash flows	-28,675	60,562
Net decrease in cash and cash equivalents	-1,632,513	-802,551
Cash and cash equivalents, beginning of period	3,745,684	3,896,087
Cash and cash equivalents, end of period	$2,113,171	$3,093,536

Unaudited_Condensed_Consolidat

Unaudited Condensed Consolidated Financial Statements	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Unaudited Condensed Consolidated Financial Statements	'
	Unaudited Condensed Consolidated Financial Statements:
	The accompanying unaudited condensed consolidated financial statements, including the notes thereto, of RBC Life Sciences, Inc. (sometimes hereinafter referred to collectively as “we”, “our”, "us", “RBC” or the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.  Certain information and disclosures that are normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted pursuant to these rules and regulations.  These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2013 (the “2013 Form 10-K”), previously filed with the Securities and Exchange Commission.
	In the opinion of management, all adjustments (consisting solely of normal recurring accruals) considered necessary for a fair presentation of the Company's results for the interim periods have been included.  The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates.  The results of operations for the interim periods presented are not necessarily indicative of the results to be expected for the full year.  Subsequent events were evaluated through the issuance date of the condensed consolidated financial statements.
	New Accounting Pronouncements:
	There were no new accounting pronouncements that are anticipated to have a material impact on the Company's financial statements.

Nature_of_Operations_and_Organ

Nature of Operations and Organization Nature of Operations and Organization	6 Months Ended
	Jun. 30, 2014
Nature of Operations and Organization [Abstract]	'
Nature of Operations and Organization	'
	Nature of Operations and Organization:
	The Company is principally engaged in the marketing of nutritional supplements and personal care products (collectively “Nutritional Products”) through subsidiaries and affiliates in North America and Southeast Asia.  This product line is marketed under the “RBC Life®” brand name.  In these markets, the Company markets its products through a network of distributors that are referred to as “Associates.”  The Associates are independent contractors who purchase products for personal use, purchase products for resale to retail customers and sponsor other individuals as Associates.  Accordingly, Associates may be product consumers only or they may also seek to derive compensation both from the direct sales of products and from sales generated by sponsored Associates. In certain other markets in Southeast Asia and Australia, the Company sells its products through a not-for-resale ("NFR") program. Individuals who participate in the NFR program function similarly to other Associates in that they can sponsor others and derive compensation from sales generated by individuals they sponsor. However, they may only order products for personal use and may not resell products to retail customers.
	RBC also markets its Nutritional Products in certain international markets through license arrangements.  The licensees are third parties who are granted exclusive rights to distribute RBC products in their respective territories and, for the most part, distribute these products through an independent Associate network in the licensed territory.  Under these arrangements, the independent Associate network in a licensed territory is compensated by the licensee.
	In addition to its Nutritional Products, RBC markets a line of wound care products (“Medical Products”) under the "MPM MedicalTM" brand name through a U.S. subsidiary.  Medical Products are distributed primarily in the United States to hospitals, nursing homes, clinics and pharmacies through traditional medical/surgical supply dealers, pharmaceutical distributors and our own sales representatives.  Medical Products are used to treat and manage pain associated with wounds in the acute care, long-term care and oncology markets.

Inventories_Inventories

Inventories Inventories	6 Months Ended
	Jun. 30, 2014
Inventory Disclosure [Abstract]	'
Inventories	'
	Inventories:
	Inventories consist of the following:
		June 30, 2014		December 31, 2013
	Raw materials and bulk products	$	259,640	$	371,863
	Packaging materials	235,172		135,138
	Finished goods	5,058,226		4,634,508
		$	5,553,038	$	5,141,509

Prepaid_Expenses_and_Other_Cur

Prepaid Expenses and Other Current Assets	6 Months Ended
	Jun. 30, 2014
Prepaid Expense and Other Assets, Current [Abstract]	'
Prepaid Expenses and Other Current Assets	'
	Prepaid Expenses and Other Current Assets:
	Prepaid expenses and other current assets consist of the following:
		June 30, 2014		December 31, 2013
	Advance payment to suppliers	$	302,198	$	202,682
	Prepaid insurance and other	350,357		164,005
	Certificates of deposit - restricted	79,620		79,909
	Prepaid income taxes	14,157		7,349
	Advances to Associates	—		339,603
		$	746,332	$	793,548
	At June 30, 2014 and December 31, 2013, the Company held certificates of deposit in the amounts of approximately $79,600 and $79,900, respectively, which were pledged to secure surety bonds.
	In 2013, the Company entered into agreements with an Associate to market Nutritional Products in Australia and certain Southeast Asia markets (the "Asia Marketing Agreements"). Pursuant to the Asia Marketing Agreements, the Company made cash advances to this Associate to support marketing and sales activities and establish product distribution facilities. These advances did not bear interest, and were to be recovered from monthly marketing fees calculated as a percentage of sales that were generated in the Associate's markets.
	On July 30, 2013, in breach of Asia Marketing Agreements, the Associate notified the Company that he was unable to fulfill his financial obligations. At the date of the breach, the Company had advanced funds to this Associate totaling approximately $403,000. Following notice of the breach, the Company continued to fund the Asia operations initiated by this Associate and charged the funding to general and administrative expenses in the periods in which the expenses were incurred.
	On March 31, 2014, the Company formally terminated the Asia Marketing Agreements and, in lieu of payment due from the Associate on the outstanding advances, took possession of property and equipment and lease deposits valued at approximately $104,000 and $43,000, respectively. The balance of the advances outstanding at March 31, 2014 was charged to general and administrative expenses.

Property_and_Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2014
Property, Plant and Equipment [Abstract]	'
Property and Equipment	'
	Property and Equipment:
	Property and equipment consists of the following:
		June 30, 2014			December 31, 2013
	Building and improvements	$	4,046,064		$	3,912,449
	Computer software and office equipment	3,231,769			2,592,382
	Warehouse equipment	254,034			254,034
	Automotive equipment	14,717			14,717
		7,546,584			6,773,582
	Less – accumulated depreciation	(4,065,425		)	(3,745,677		)
		3,481,159			3,027,905
	Land	1,141,173			1,141,173
		$	4,622,332		$	4,169,078
	Depreciation expense totaled approximately $149,400 and $145,500 for the quarters ended June 30, 2014 and 2013, respectively, and $287,300 and $291,400 for the six months ended June 30, 2014 and 2013, respectively.

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets	6 Months Ended
	Jun. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Other Intangible Assets	'
	Goodwill and Other Intangible Assets:
	The Company measures its goodwill for impairment at the end of each year or in the event of an impairment indicator.  No impairment losses have been recognized as a result of this testing.  Goodwill balances are summarized as follows:
		Gross Carrying Value				Accumulated Amortization
	Balance, December 31, 2013	$	3,367,863			$	(1,104,405	)
	Currency translation adjustment	(3,577		)		1,743
	Balance, June 30, 2014	$	3,364,286			$	(1,102,662	)
	Other intangible assets consist of the following:
				June 30, 2014							December 31, 2013
		Average		Gross				Accumulated			Gross		Accumulated
		Life		Carrying				Amortization			Carrying		Amortization
		(years)		Value							Value
	Copyrights, trademarks and other registrations	19		$	99,100			$	(68,048	)	$	99,100	$	(65,405	)
	Business license	1		40,508				(12,738		)	—		—
	Other	19		12,600				(8,652		)	12,600		(8,316		)
				$	152,208			$	(89,438	)	$	111,700	$	(73,721	)
	Amortization expense related to other intangible assets totaled approximately $11,100 and $1,500 for the quarters ended June 30, 2014 and 2013, respectively, and $15,700 and $3,000 for the six months ended June 30, 2014 and 2013, respectively. The aggregate estimated amortization expense for intangible assets remaining as of June 30, 2014 is as follows:
	Remainder of 2014	$	22,086
	2015	14,619
	2016	5,957
	2017	5,957
	2018	5,957
	Thereafter	8,194
		$	62,770

Accrued_Liabilities

Accrued Liabilities	6 Months Ended
	Jun. 30, 2014
Accrued Liabilities [Abstract]	'
Accrued Liabilities	'
	Accrued Liabilities:
	Accrued liabilities consist of the following:
		June 30, 2014		December 31, 2013
	Distributor commissions and awards	$	1,060,108	$	507,365
	Salaries and wages	434,150		502,303
	Sales and property taxes	94,854		83,159
	Medical products sales rebates	45,747		35,340
	Interest	8,038		8,711
	Other	50,271		19,940
		$	1,693,168	$	1,156,818

LongTerm_Obligations

Long-Term Obligations	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Long-Term Obligations	'
	Long-Term Obligations:
	Long-term obligations consist of the following:
		June 30, 2014			December 31, 2013
	Mortgage note payable bearing interest at 7.75%, payable in monthly installments of $25,797 through April 2019, collateralized by land and building, and personally guaranteed by the Company’s Chairman of the Board of Directors and Chief Executive Officer	$	1,244,635		$	1,348,821
	Less – current maturities	(220,841		)	(212,474		)
		$	1,023,794		$	1,136,347
	The fair value of long-term debt is estimated based on interest rates for the same or similar instruments offered having the same or similar maturities and collateral requirements.  At June 30, 2014, the fair value of fixed-rate long-term debt was approximately $1,359,000, which was $114,000 above the carrying value of approximately $1,245,000.  At December 31, 2013, the fair value of fixed-rate long-term debt was approximately $1,469,000, which was $120,000 above the carrying value of approximately$1,349,000.

ShareBased_Compensation

Share-Based Compensation	6 Months Ended
	Jun. 30, 2014
Share-based Compensation [Abstract]	'
Share-Based Compensation	'
	Share-Based Compensation:
	The Company records compensation expense for all share-based payments based on the estimated grant date fair value.  Share-based compensation expense was approximately $1,300 and $4,800 for the quarters ended June 30, 2014 and 2013, respectively, and $2,100 and $9,500 for the six months ended June 30, 2014 and 2013, respectively.  Share-based compensation is classified as a general and administrative expense.  There were no material tax benefits related to this expense because virtually all share-based compensation resulted from grants of incentive stock options.
	The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions:
		Quarters Ended June 30,				Six Months Ended June 30,
		2014		2013		2014		2013
		-1		-1		-1		-1
	Weighted average expected life (years)	—		—		—		—
	Risk-free interest rate	—	%	—	%	—	%	—	%
	Expected volatility	—	%	—	%	—	%	—	%
	Expected dividend yield	—	%	—	%	—	%	—	%
	__________________
	(1) There were no option grants during these periods.
	All share numbers and per share amounts presented reflect the reverse and forward stock splits of the Company that were affected on August 9, 2013. A summary of stock option activity for the six months ended June 30, 2014 is as follows:
		Options		Weighted-Average Exercise Price per Share			Weighted-Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
	Outstanding on December 31, 2013	69,396		$	4
	Granted	—		—
	Exercised	—		—
	Forfeited/canceled	(15,500	)	3.2
	Outstanding on June 30, 2014	53,896		$	4.2		4	$	—
	Exercisable on June 30, 2014	53,896		$	4.2		3.2	$	—
	A summary of the status of the Company's non-vested stock options as of June 30, 2014 and changes during the six months then ended are presented below:
		Shares		Weighted-Average Grant Date Fair Value per Share
	Non-vested stock options at December 31, 2013	14,750		$	2.68
	Non-vested stock options granted	—		—
	Vested stock options	—		—
	Forfeited stock options	(14,750	)	2.68
	Non-vested stock options at June 30, 2014	—		$	—
	As of June 30, 2014, there was no unrecognized compensation cost related to stock option grants.

Segments_and_Geographic_Area

Segments and Geographic Area	6 Months Ended
	Jun. 30, 2014
Segment Reporting [Abstract]	'
Segments and Geographic Area	'
	Segments and Geographic Area:
	The Company's segments are based on the organizational structure that is used by management for making operating and investment decisions and for assessing performance.  Based on this structure, the Company has two operating segments: Nutritional Products and Medical Products.
	The Nutritional Products segment manufactures and distributes a line of approximately 100 nutritional supplements and personal care products, including herbs, vitamins and minerals, as well as natural skin, hair and body care products.  Nutritional Products are marketed under the "RBC Life" brand name through subsidiaries in North America and Southeast Asia.  These products are distributed by a network comprised of independent Associates and NFR program participants in certain markets, primarily the U.S., Canada and Southeast Asia, and by licensees in other international markets.  For the most part, licensees also market the Nutritional Products in their respective territories through a network of independent Associates.
	The Medical Products segment markets a line of over 35 wound care products under the "MPM Medical" brand name through a subsidiary operating primarily in the U.S.  These wound care products are distributed to hospitals, nursing homes, home health care agencies, clinics and pharmacies through a network of medical/surgical supply dealers, pharmaceutical distributors and our own sales representatives.  Medical Products are used to treat and manage pain associated with wounds, in the acute care, long-term care and oncology markets.
	The Company evaluates the performance of its segments primarily based on operating profit.  All intercompany transactions have been eliminated, and intersegment revenues are not significant.  In calculating operating profit for these two segments, administrative expenses incurred that are common to the two segments are allocated on a usage basis.
	Segment information is as follows (U.S. dollars in 000s):
		Nutritional Products			Medical Products			Consolidated
	Quarter Ended June 30, 2014
	Net sales	$	6,392		$	1,493		$	7,885
	Depreciation and amortization	135			16			151
	Operating income (loss)	48			(15		)	33
	Capital expenditures	333			—			333
	Total assets	13,655			3,089			16,744
	Quarter Ended June 30, 2013
	Net sales	$	5,102		$	1,592		$	6,694
	Depreciation and amortization	131			16			147
	Operating income (loss)	(205		)	7			(198		)
	Capital expenditures	11			—			11
	Total assets	14,167			2,790			16,957
	Six Months Ended June 30, 2014
	Net sales	$	10,514		$	3,084		$	13,598
	Depreciation and amortization	259			31			290
	Operating income (loss)	(496		)	37			(459		)
	Capital expenditures	636			—			636
	Total assets	13,655			3,089			16,744
	Six Months Ended June 30, 2013
	Net sales	$	9,432		$	2,954		$	12,386
	Depreciation and amortization	263			31			294
	Operating loss	(157		)	(17		)	(174		)
	Capital expenditures	11			—			11
	Total assets	14,167			2,790			16,957
	Financial information summarized geographically is as follows (U.S. dollars in 000s):
		Quarter Ended June 30, 2014						Quarter Ended June 30, 2013
		Net sales			Long-Lived assets			Net sales			Long-Lived assets
	Domestic	$	2,219		$	6,087		$	2,436		$	6,069
	Russia/Eastern Europe	3,342			—			3,259			—
	Canada	328			505			408			517
	Southeast Asia	1,937			456			552			66
	All others	59			—			39			—
	Totals	$	7,885		$	7,048		$	6,694		$	6,652
		Six Months Ended June 30, 2014						Six Months Ended June 30, 2013
		Net sales			Long-Lived assets			Net sales			Long-Lived assets
	Domestic	$	4,533		$	6,087		$	4,675		$	6,069
	Russia/Eastern Europe	5,352			—			5,777			—
	Canada	661			505			810			517
	Southeast Asia	2,928			456			1,040			66
	All others	124			—			84			—
	Totals	$	13,598		$	7,048		$	12,386		$	6,652
	Significant Customers
	The Company recorded sales of Nutritional Products to Coral Club International, Inc. ("CCI"), a licensee of the Company, in the amounts of $3,342,000 and $3,259,000 during the quarters ended June 30, 2014 and 2013, respectively, and $5,352,000 and $5,777,000 during the six months ended June 30, 2014 and 2013, respectively.  The President of CCI is a former member of our Board of Directors and beneficially owns approximately 18% of our Common Stock. The Company also recorded sales of Medical Products to a medical/surgical dealer (see Note L for additional information related to this dealer) in the amounts of $711,000 and $671,000 during the quarters ended June 30, 2014 and 2013, respectively, and $1,391,000 and $1,288,000 during the six months ended June 30, 2014 and 2013, respectively.  In no other case did a customer of the Company account for more than 10% of net sales during the quarters or the six months ended June 30, 2014 and 2013.

Earnings_Loss_Per_Share

Earnings (Loss) Per Share	6 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Earnings (Loss) Per Share	'
	Loss Per Share:
	Summarized basic and diluted loss per common share was calculated as follows:
		Net Loss			Weighted	Per Share
					Average
					Shares
	Quarter Ended June 30, 2014
	Basic loss per common share	$	(6,644	)	2,212,350	$	(0.00	)
	Effect of dilutive stock options	—			—
	Diluted loss per common share	$	(6,644	)	2,212,350	$	(0.00	)
	Quarter Ended June 30, 2013
	Basic loss per common share	$	(147,304	)	2,222,883	$	(0.07	)
	Effect of dilutive stock options	—			—
	Diluted loss per common share	$	(147,304	)	2,222,883	$	(0.07	)
	Six Months Ended June 30, 2014
	Basic loss per common share	$	(384,532	)	2,212,350	$	(0.17	)
	Effect of dilutive stock options	—			—
	Diluted loss per common share	$	(384,532	)	2,212,350	$	(0.17	)
	Six Months Ended June 30, 2013
	Basic loss per common share	$	(154,980	)	2,222,883	$	(0.07	)
	Effect of dilutive stock options	—			—
	Diluted loss per common share	$	(154,980	)	2,222,883	$	(0.07	)
	The average number of stock options that were outstanding, but not included in the computation of diluted loss per common share because their exercise price was greater than the average market price of the common stock, or were otherwise anti-dilutive, was approximately 61,400 and 76,000 for the quarters ended June 30, 2014 and 2013, respectively, and 61,400 and 78,600 for the six months ended June 30, 2014 and 2013, respectively.

Legal_Proceedings

Legal Proceedings	6 Months Ended
	Jun. 30, 2014
Legal Proceedings [Abstract]	'
Legal Proceedings	'
	Legal Proceedings:
	Medical/Surgical Dealer
	One medical/surgical dealer accounts for a significant portion of Medical Products sales. This dealer distributes our Medical Products and provides services primarily to nursing homes and obtains reimbursement for the price of our products from Medicare. This dealer accounted for approximately $1,391,000 and $1,288,000 of the Company's net sales during the six months ended June 30, 2014 and 2013, respectively, which was approximately 10% of consolidated net sales in both periods.
	On February 27, 2012, we were notified that this dealer filed a voluntary petition for protection under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the Central District of California in Santa Ana, California on February 24, 2012. According to its bankruptcy petition, this dealer filed its petition as the most effective means of stabilizing its finances as it resolves a reimbursement guidelines dispute with Medicare, which the dealer believes is improperly withholding payments. The petition states that this dealer relies on Medicare payments for more than 90% of its revenue and that Medicare had suspended payments to the dealer. In a press release issued by the dealer at the time of the filing, the dealer stated that the Chapter 11 filing will allow it to continue operating without interruption while it resolves its payment dispute with Medicare as expeditiously as possible. As of June 30, 2014, this dealer owed to the Company approximately $240,000 in pre-petition accounts receivable. In July 2014, pursuant to an arrangement approved by the Bankruptcy Court, this pre-petition accounts receivable balance was paid in full. We continue to fill this dealer's post-petition orders, with payments received in accordance with our normal terms.
	Environmental Research Center
	On April 4, 2014, the Company received a notice from the Environmental Research Center, a California non-profit corporation alleging that the Company failed to include a warning notice related to lead content on labels of certain nutritional products sold in California as required under California's Safe Drinking Water and Toxic Enforcement Act of 1986 ("Proposition 65").
	This non-profit organization seeks an agreement from the Company to reformulate or label the listed products distributed in California in accordance with Proposition 65 and pay an appropriate civil penalty related to sales in California of allegedly improperly labeled products since April 4, 2011.
	The Company is currently assessing the validity of this allegation and is unable at this time to reasonably estimate the financial impact, if any, related to this matter.
	From time to time, we are a party to claims, litigation or other legal or administrative proceedings that we consider to arise in the ordinary course of our business. No assurances can be given regarding the outcome of these or any other pending proceedings, or the ultimate effect such outcomes may have. However, other than as stated above, we do not believe we are a party to any legal or administrative proceedings which, if determined adversely to us, individually or in the aggregate, would have a material effect on our financial position, results of operations or cash flows.

Unaudited_Condensed_Consolidat1

Unaudited Condensed Consolidated Financial Statements (Policies)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
New Accounting Pronouncements	'
	New Accounting Pronouncements:
	There were no new accounting pronouncements that are anticipated to have a material impact on the Company's financial statements.

Inventories_Tables

Inventories (Tables)	6 Months Ended
	Jun. 30, 2014
Inventory Disclosure [Abstract]	'
Schedule of Inventories	'
	Inventories consist of the following:
		June 30, 2014		December 31, 2013
	Raw materials and bulk products	$	259,640	$	371,863
	Packaging materials	235,172		135,138
	Finished goods	5,058,226		4,634,508
		$	5,553,038	$	5,141,509

Prepaid_Expenses_and_Other_Cur1

Prepaid Expenses and Other Current Assets (Tables)	6 Months Ended
	Jun. 30, 2014
Prepaid Expense and Other Assets, Current [Abstract]	'
Schedule of Prepaid Expenses and Other Current Assets	'
	Prepaid expenses and other current assets consist of the following:
		June 30, 2014		December 31, 2013
	Advance payment to suppliers	$	302,198	$	202,682
	Prepaid insurance and other	350,357		164,005
	Certificates of deposit - restricted	79,620		79,909
	Prepaid income taxes	14,157		7,349
	Advances to Associates	—		339,603
		$	746,332	$	793,548

Property_and_Equipment_Tables

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2014
Property, Plant and Equipment [Abstract]	'
Schedule of Property and Equipment	'
	Property and equipment consists of the following:
		June 30, 2014			December 31, 2013
	Building and improvements	$	4,046,064		$	3,912,449
	Computer software and office equipment	3,231,769			2,592,382
	Warehouse equipment	254,034			254,034
	Automotive equipment	14,717			14,717
		7,546,584			6,773,582
	Less – accumulated depreciation	(4,065,425		)	(3,745,677		)
		3,481,159			3,027,905
	Land	1,141,173			1,141,173
		$	4,622,332		$	4,169,078

Goodwill_and_Other_Intangible_1

Goodwill and Other Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Summary of Goodwill Balances	'
	Goodwill balances are summarized as follows:
		Gross Carrying Value				Accumulated Amortization
	Balance, December 31, 2013	$	3,367,863			$	(1,104,405	)
	Currency translation adjustment	(3,577		)		1,743
	Balance, June 30, 2014	$	3,364,286			$	(1,102,662	)
Schedule of Other Intangible Assets	'
	Other intangible assets consist of the following:
				June 30, 2014							December 31, 2013
		Average		Gross				Accumulated			Gross		Accumulated
		Life		Carrying				Amortization			Carrying		Amortization
		(years)		Value							Value
	Copyrights, trademarks and other registrations	19		$	99,100			$	(68,048	)	$	99,100	$	(65,405	)
	Business license	1		40,508				(12,738		)	—		—
	Other	19		12,600				(8,652		)	12,600		(8,316		)
				$	152,208			$	(89,438	)	$	111,700	$	(73,721	)
Schedule of Aggregate Estimated Amortization Expense	'
	The aggregate estimated amortization expense for intangible assets remaining as of June 30, 2014 is as follows:
	Remainder of 2014	$	22,086
	2015	14,619
	2016	5,957
	2017	5,957
	2018	5,957
	Thereafter	8,194
		$	62,770

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2014
Accrued Liabilities [Abstract]	'
Schedule of Accrued Liabilities	'
	Accrued liabilities consist of the following:
		June 30, 2014		December 31, 2013
	Distributor commissions and awards	$	1,060,108	$	507,365
	Salaries and wages	434,150		502,303
	Sales and property taxes	94,854		83,159
	Medical products sales rebates	45,747		35,340
	Interest	8,038		8,711
	Other	50,271		19,940
		$	1,693,168	$	1,156,818

LongTerm_Obligations_Tables

Long-Term Obligations (Tables)	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Schedule of Long-term Obligations	'
	Long-term obligations consist of the following:
		June 30, 2014			December 31, 2013
	Mortgage note payable bearing interest at 7.75%, payable in monthly installments of $25,797 through April 2019, collateralized by land and building, and personally guaranteed by the Company’s Chairman of the Board of Directors and Chief Executive Officer	$	1,244,635		$	1,348,821
	Less – current maturities	(220,841		)	(212,474		)
		$	1,023,794		$	1,136,347

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2014
Share-based Compensation [Abstract]	'
Schedule of Fair Value of Option Grants	'
	The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions:
		Quarters Ended June 30,				Six Months Ended June 30,
		2014		2013		2014		2013
		-1		-1		-1		-1
	Weighted average expected life (years)	—		—		—		—
	Risk-free interest rate	—	%	—	%	—	%	—	%
	Expected volatility	—	%	—	%	—	%	—	%
	Expected dividend yield	—	%	—	%	—	%	—	%
	__________________
	(1) There were no option grants during these periods.
Schedule of Stock Option Activity	'
	A summary of stock option activity for the six months ended June 30, 2014 is as follows:
		Options		Weighted-Average Exercise Price per Share			Weighted-Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
	Outstanding on December 31, 2013	69,396		$	4
	Granted	—		—
	Exercised	—		—
	Forfeited/canceled	(15,500	)	3.2
	Outstanding on June 30, 2014	53,896		$	4.2		4	$	—
	Exercisable on June 30, 2014	53,896		$	4.2		3.2	$	—
Schedule of Nonvested Share Activity	'
	A summary of the status of the Company's non-vested stock options as of June 30, 2014 and changes during the six months then ended are presented below:
		Shares		Weighted-Average Grant Date Fair Value per Share
	Non-vested stock options at December 31, 2013	14,750		$	2.68
	Non-vested stock options granted	—		—
	Vested stock options	—		—
	Forfeited stock options	(14,750	)	2.68
	Non-vested stock options at June 30, 2014	—		$	—

Segments_and_Geographic_Area_T

Segments and Geographic Area (Tables)	6 Months Ended
	Jun. 30, 2014
Segment Reporting [Abstract]	'
Schedule of Segment Information	'
	Segment information is as follows (U.S. dollars in 000s):
		Nutritional Products			Medical Products			Consolidated
	Quarter Ended June 30, 2014
	Net sales	$	6,392		$	1,493		$	7,885
	Depreciation and amortization	135			16			151
	Operating income (loss)	48			(15		)	33
	Capital expenditures	333			—			333
	Total assets	13,655			3,089			16,744
	Quarter Ended June 30, 2013
	Net sales	$	5,102		$	1,592		$	6,694
	Depreciation and amortization	131			16			147
	Operating income (loss)	(205		)	7			(198		)
	Capital expenditures	11			—			11
	Total assets	14,167			2,790			16,957
	Six Months Ended June 30, 2014
	Net sales	$	10,514		$	3,084		$	13,598
	Depreciation and amortization	259			31			290
	Operating income (loss)	(496		)	37			(459		)
	Capital expenditures	636			—			636
	Total assets	13,655			3,089			16,744
	Six Months Ended June 30, 2013
	Net sales	$	9,432		$	2,954		$	12,386
	Depreciation and amortization	263			31			294
	Operating loss	(157		)	(17		)	(174		)
	Capital expenditures	11			—			11
	Total assets	14,167			2,790			16,957
Summary of Financial Information by Geographic Segment	'
	Financial information summarized geographically is as follows (U.S. dollars in 000s):
		Quarter Ended June 30, 2014						Quarter Ended June 30, 2013
		Net sales			Long-Lived assets			Net sales			Long-Lived assets
	Domestic	$	2,219		$	6,087		$	2,436		$	6,069
	Russia/Eastern Europe	3,342			—			3,259			—
	Canada	328			505			408			517
	Southeast Asia	1,937			456			552			66
	All others	59			—			39			—
	Totals	$	7,885		$	7,048		$	6,694		$	6,652
		Six Months Ended June 30, 2014						Six Months Ended June 30, 2013
		Net sales			Long-Lived assets			Net sales			Long-Lived assets
	Domestic	$	4,533		$	6,087		$	4,675		$	6,069
	Russia/Eastern Europe	5,352			—			5,777			—
	Canada	661			505			810			517
	Southeast Asia	2,928			456			1,040			66
	All others	124			—			84			—
	Totals	$	13,598		$	7,048		$	12,386		$	6,652

Earnings_Loss_Per_Share_Tables

Earnings (Loss) Per Share (Tables)	6 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Schedule of Basic and Diluted Earnings (Loss) Per Common Share	'
	Summarized basic and diluted loss per common share was calculated as follows:
		Net Loss			Weighted	Per Share
					Average
					Shares
	Quarter Ended June 30, 2014
	Basic loss per common share	$	(6,644	)	2,212,350	$	(0.00	)
	Effect of dilutive stock options	—			—
	Diluted loss per common share	$	(6,644	)	2,212,350	$	(0.00	)
	Quarter Ended June 30, 2013
	Basic loss per common share	$	(147,304	)	2,222,883	$	(0.07	)
	Effect of dilutive stock options	—			—
	Diluted loss per common share	$	(147,304	)	2,222,883	$	(0.07	)
	Six Months Ended June 30, 2014
	Basic loss per common share	$	(384,532	)	2,212,350	$	(0.17	)
	Effect of dilutive stock options	—			—
	Diluted loss per common share	$	(384,532	)	2,212,350	$	(0.17	)
	Six Months Ended June 30, 2013
	Basic loss per common share	$	(154,980	)	2,222,883	$	(0.07	)
	Effect of dilutive stock options	—			—
	Diluted loss per common share	$	(154,980	)	2,222,883	$	(0.07	)

Inventories_Details

Inventories (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Inventory Disclosure [Abstract]	'	'
Raw materials and bulk products	$259,640	$371,863
Packaging materials	235,172	135,138
Finished goods	5,058,226	4,634,508
Inventories	$5,553,038	$5,141,509

Prepaid_Expenses_and_Other_Cur2

Prepaid Expenses and Other Current Assets (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Jul. 30, 2013	Mar. 31, 2014	Mar. 31, 2014
			Hong Kong	Hong Kong	Leasehold Improvements and Furniture and Fixtures
					Hong Kong
Prepaid Expenses and Other Current Assets [Line Items]	'	'	'	'	'
Advance payment to suppliers	$302,198	$202,682	'	'	'
Prepaid insurance and other	350,357	164,005	'	'	'
Certificates of deposit - restricted	79,620	79,909	'	'	'
Prepaid income taxes	14,157	7,349	'	'	'
Advances to Associates	0	339,603	'	'	'
Prepaid expenses and other current assets	746,332	793,548	'	'	'
Advances to Associates	'	'	403,000	'	'
Property and equipment, net	4,622,332	4,169,078	'	'	104,000
Claims to recover lease deposits	'	'	'	$43,000	'

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property and equipment, net	$4,622,332	'	$4,622,332	'	$4,169,078
Depreciation expense	149,400	145,500	287,300	291,400	'
Building and improvements	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property and equipment, gross	4,046,064	'	4,046,064	'	3,912,449
Computer software and office equipment	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property and equipment, gross	3,231,769	'	3,231,769	'	2,592,382
Warehouse equipment	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property and equipment, gross	254,034	'	254,034	'	254,034
Automotive equipment	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property and equipment, gross	14,717	'	14,717	'	14,717
Depreciable Assets	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property and equipment, gross	7,546,584	'	7,546,584	'	6,773,582
Less: accumulated depreciation	-4,065,425	'	-4,065,425	'	-3,745,677
Property and equipment, net	3,481,159	'	3,481,159	'	3,027,905
Land	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property and equipment, net	$1,141,173	'	$1,141,173	'	$1,141,173

Goodwill_and_Other_Intangible_2

Goodwill and Other Intangible Assets (Summary of Goodwill Balances) (Details) (USD $)	6 Months Ended
	Jun. 30, 2014
Goodwill [Roll Forward]	'
Gross Carrying Value, Beginning Balance	$3,367,863
Gross Carrying Value, Currency translation adjustment	-3,577
Gross Carrying Value, Ending Balance	3,364,286
Accumulated Amortization, Beginning Balance	-1,104,405
Accumulated Amortization, Currency translation adjustment	1,743
Accumulated Amortization, Ending Balance	($1,102,662)

Goodwill_and_Other_Intangible_3

Goodwill and Other Intangible Assets (Summary of Other Intangible Assets) (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
Gross Carrying Value	$152,208	'	$152,208	'	$111,700
Accumulated Amortization	-89,438	'	-89,438	'	-73,721
Amortization expense	11,100	1,500	15,700	3,000	'
Copyrights, trademarks and other registrations	'	'	'	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
Average Life (years)	'	'	'19 years	'	'
Gross Carrying Value	99,100	'	99,100	'	99,100
Accumulated Amortization	-68,048	'	-68,048	'	-65,405
Business license	'	'	'	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
Average Life (years)	'	'	'1 year	'	'
Gross Carrying Value	40,508	'	40,508	'	0
Accumulated Amortization	-12,738	'	-12,738	'	0
Other	'	'	'	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
Average Life (years)	'	'	'19 years	'	'
Gross Carrying Value	12,600	'	12,600	'	12,600
Accumulated Amortization	($8,652)	'	($8,652)	'	($8,316)

Goodwill_and_Other_Intangible_4

Goodwill and Other Intangible Assets (Aggregate Estimated Amortization) (Details) (USD $)	Jun. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Remainder of 2014	$22,086
2015	14,619
2016	5,957
2017	5,957
2018	5,957
Thereafter	8,194
Aggregate estimated amortization expense	$62,770

Accrued_Liabilities_Details

Accrued Liabilities (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Accrued Liabilities [Abstract]	'	'
Distributor commissions and awards	$1,060,108	$507,365
Salaries and wages	434,150	502,303
Sales and property taxes	94,854	83,159
Medical products sales rebates	45,747	35,340
Interest	8,038	8,711
Other	50,271	19,940
Accrued liabilities	$1,693,168	$1,156,818

LongTerm_Obligations_Details

Long-Term Obligations (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Debt Instrument [Line Items]	'	'
Long-term Debt	$1,244,635	$1,348,821
Less b current maturities	-220,841	-212,474
Long-term obligations, less current maturities	1,023,794	1,136,347
Fair value of fixed-rate long-term debt	1,359,000	1,469,000
Fair value in excess of carrying value	114,000	120,000
Mortgage Notes Payable	'	'
Debt Instrument [Line Items]	'	'
Interest rate (as a percentage)	7.75%	7.75%
Monthly installment payments	$25,797	$25,797

ShareBased_Compensation_Summar

Share-Based Compensation (Summary of Fair Value of Option Grants) (Details) (USD $)	3 Months Ended				6 Months Ended
	Jun. 30, 2014		Jun. 30, 2013		Jun. 30, 2014		Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'		'		'		'
Share-based compensation expense	$1,300		$4,800		$2,100		$9,500
Stock Options	'		'		'		'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'		'		'		'
Weighted average expected life (years)	'0 years	[1]	'0 years	[1]	'0 years	[1]	'0 years	[1]
Risk-free interest rate (percent)	0.00%	[1]	0.00%		0.00%	[1]	0.00%	[1]
Expected volatility (percent)	0.00%	[1]	0.00%		0.00%	[1]	0.00%	[1]
Expected dividend yield (percent)	0.00%	[1]	0.00%		0.00%	[1]	0.00%	[1]
[1]	There were no option grants during these periods.

ShareBased_Compensation_Summar1

Share-Based Compensation (Summary of Stock Option Activity) (Details) (USD $)	6 Months Ended
	Jun. 30, 2014
Options, Outstanding [Roll Forward]	'
Options, Beginning Balance Outstanding	69,396
Options, Granted	0
Options, Exercised	0
Options, Forfeited/canceled	-15,500
Options, Ending Balance Outstanding	53,896
Options, Exercisable	53,896
Outstanding, Weighted-Average Exercise Price per Share [Roll Forward]	'
Weighted-Average Exercise Price per Share, Beginning Balance Outstanding	$4
Weighted-Average Exercise Price per Share, Granted	$0
Weighted-Average Exercise Price per Share, Exercised	$0
Weighted-Average Exercise Price per Share, Forfeited/canceled	$3.20
Weighted-Average Exercise Price per Share, Ending Balance Outstanding	$4.20
Weighted-Average Exercise Price per Share, Exercisable	$4.20
Weighted-Average Remaining Contractual Term, Outstanding	'4 years 0 months
Weighted-Average Remaining Contractual Term, Exercisable	'3 years 2 months 12 days
Aggregate Intrinsic Value, Outstanding	$0
Aggregate Intrinsic Value, Exercisable	$0

ShareBased_Compensation_Summar2

Share-Based Compensation (Summary of Non-vested Stock Options) (Details) (USD $)	6 Months Ended
	Jun. 30, 2014
Non-vested Stock Options, Number of Shares [Roll Forward]	'
Shares, Non-vested stock options, Beginning Balance	14,750
Shares, Non-vested stock options granted	0
Shares, Vested stock options	0
Shares, Forfeited stock options	-14,750
Shares, Non-vested stock options, Ending Balance	0
Non-vested Stock Options, Weighted Average Grant Date Fair Value [Roll Forward]	'
Weighted Average Grant Date Fair Value per Share, Non-vested stock options, Beginning Balance	$2.68
Weighted Average Grant Date Fair Value per Share, Non-vested stock options granted	$0
Weighted Average Grant Date Fair Value per Share, Vested stock options	$0
Weighted Average Grant Date Fair Value per Share, Forfeited stock options	$2.68
Weighted Average Grant Date Fair Value per Share, Non-vested stock options, Ending Balance	$0

Segments_and_Geographic_Area_S

Segments and Geographic Area (Summary of Segment Information) (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
			segment
Segment Reporting Information [Line Items]	'	'	'	'	'
Number of operating segments (segment)	'	'	2	'	'
Net sales	$7,885,090	$6,694,319	$13,598,210	$12,385,500	'
Depreciation and amortization	150,849	147,335	290,300	294,343	'
Operating income (loss)	33,190	-197,852	-459,004	-174,432	'
Capital expenditures	332,505	11,292	636,170	11,292	'
Total assets	16,744,149	16,957,431	16,744,149	16,957,431	17,533,510
Nutritional Products	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Net sales	6,392,000	5,102,000	10,514,000	9,432,000	'
Depreciation and amortization	135,000	131,000	259,000	263,000	'
Operating income (loss)	48,000	-205,000	-496,000	-157,000	'
Capital expenditures	333,000	11,000	636,000	11,000	'
Total assets	13,655,000	14,167,000	13,655,000	14,167,000	14,167,000
Medical Products	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Net sales	1,493,000	1,592,000	3,084,000	2,954,000	'
Depreciation and amortization	16,000	16,000	31,000	31,000	'
Operating income (loss)	-15,000	7,000	37,000	-17,000	'
Capital expenditures	0	0	0	0	'
Total assets	$3,089,000	$2,790,000	$3,089,000	$2,790,000	$2,790,000
Minimum | Nutritional Products	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Number of products (products)	'	'	100	'	'
Wound Care Products | Medical Products	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Number of products (products)	'	'	35	'	'

Segments_and_Geographic_Area_S1

Segments and Geographic Area (Summary of Financial Information by Geographic Location) (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Segment Reporting Information [Line Items]	'	'	'	'	'
Net sales	$7,885,090	$6,694,319	$13,598,210	$12,385,500	'
Long-Lived assets	7,048,000	6,652,000	7,048,000	6,652,000	6,652,000
Domestic	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Net sales	2,219,000	2,436,000	4,533,000	4,675,000	'
Long-Lived assets	6,087,000	6,069,000	6,087,000	6,069,000	6,069,000
Russia/Eastern Europe	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Net sales	3,342,000	3,259,000	5,352,000	5,777,000	'
Long-Lived assets	0	0	0	0	0
Canada	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Net sales	328,000	408,000	661,000	810,000	'
Long-Lived assets	505,000	517,000	505,000	517,000	517,000
Southeast Asia	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Net sales	1,937,000	552,000	2,928,000	1,040,000	'
Long-Lived assets	456,000	66,000	456,000	66,000	66,000
All others	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Net sales	59,000	39,000	124,000	84,000	'
Long-Lived assets	$0	$0	$0	$0	$0

Segments_and_Geographic_Area_S2

Segments and Geographic Area (Summary Significant Customers) (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Segment Reporting Information [Line Items]	'	'	'	'
Net sales	$7,885,090	$6,694,319	$13,598,210	$12,385,500
Nutritional Products	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Net sales	6,392,000	5,102,000	10,514,000	9,432,000
Medical Products	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Net sales	1,493,000	1,592,000	3,084,000	2,954,000
Coral Club International, Inc. | Nutritional Products	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Net sales	3,342,000	3,259,000	5,352,000	5,777,000
Medical/Surgical Dealer | Medical Products	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Net sales	$711,000	$671,000	$1,391,000	$1,288,000
President of Related Entity and Former Director	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Ownership percentage (percent)	18.00%	'	18.00%	'

Earnings_Loss_Per_Share_Detail

Earnings (Loss) Per Share (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Earnings Per Share [Abstract]	'	'	'	'
Net Earnings (Loss), Basic	($6,644)	($147,304)	($384,532)	($154,980)
Net Earnings (Loss), Diluted	($6,644)	($147,304)	($384,532)	($154,980)
Weighted average shares, basic (shares)	2,212,350	2,222,883	2,212,350	2,222,883
Weighted average shares, effect of dilutive stock options (shares)	'	'	0	0
Weighted average shares, diluted (shares)	2,212,350	2,222,883	2,212,350	2,222,883
Earnings per share, basic (usd per share)	$0	($0.07)	($0.17)	($0.07)
Earnings per share, diluted (usd per share)	$0	($0.07)	($0.17)	($0.07)
Antidilutive stock options excluded from earnings per share calculation	61,400	76,000	61,400	78,600

Legal_Proceedings_Details

Legal Proceedings (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Loss Contingencies [Line Items]	'	'	'	'
Net sales	$7,885,090	$6,694,319	$13,598,210	$12,385,500
Percentage of revenue (percent)	'	'	90.00%	'
Pre-petition accounts receivable	240,000	'	240,000	'
Medical Products	'	'	'	'
Loss Contingencies [Line Items]	'	'	'	'
Net sales	1,493,000	1,592,000	3,084,000	2,954,000
Medical/Surgical Dealer | Medical Products	'	'	'	'
Loss Contingencies [Line Items]	'	'	'	'
Net sales	$711,000	$671,000	$1,391,000	$1,288,000
Concentration Rrisk (percent)	'	'	10.00%	'